Connect with us


Biogenera Raises €3 Million From Over 600 Investors

Innovative SME Biogenera successfully closes its third equity crowdfunding round on Crowdfundme with nearly $3.5 million (€3 million) and over 600 investors. Biogenera has conceived and developed MyGeneraTM, a unique and highly innovative proprietary biotechnology platform that enables the identification of novel DNA drugs that act directly by blocking mutated genes that cause disease.



Biogenera, an innovative SME specialized in the creation and development of personalized DNA drugs for the treatment of diseases considered incurable until now, has successfully closed its third round of equity crowdfunding with a large participation of small and large investors. The collection, carried out on the CrowdFundMe portal, reached $3.4 million (€2.9 million), thanks to the participation of 644 investors.

Biogenera had previously launched two other successful campaigns, launched through the vehicle Provita Srl: the first, in 2017 on 200Crowd, had raised $442,000 (€380,000) from 95 investors; the second, in 2018 on Backtowork, had exceeded $814,000 (€700,000) thanks to 73 investors.

For this third round on CrowdFundMe, the pre-money valuation was a whopping $81.4 million (€70 million). This valuation is most likely due to the fact that the company has successfully concluded the preclinical studies of the most advanced anti-tumor drug BGA002 and obtained the orphan drug designation for the treatment of the deadliest children’s cancer (Neuroblastoma), from the US EMA and FDA, and for the treatment of soft part sarcomas (from the EMA) as well as small cell lung cancer (from the FDA). In addition, it has more than 50 international patents approved, including the anti-cancer drugs BGA002 and BGA003 and other new drug candidates. Finally, Biogenera is in contact with several international pharmaceutical companies, with the aim of establishing one or more strategic agreements as early as in the next 12 months.

Strengthened by these results, the SME has started the process of listing on Euronext in order to aim at both international growth and increased visibility with the possibility, therefore, to create agreements and strategic collaborations with other pharmaceutical companies.

Read more on the subject and find the latest business headlines with our companion app Born2Invest.

The involvement of investors has been one of the most remarkable successes of this third round

In addition to the absolute number, 644, already a record (second campaign for a number of investors in 2021 excluding real estate projects and investment vehicles), it should be noted that, given the very low minimum chip (€500), the investments are very well distributed: 2% of investors (11), with an average of $105,000 (€90,000) each contributed 34.5% of the collection; 13% (83), with an average of $14,000 (€12,000) each contributed another 34.5%; 85% (550) invested an average of $1,860 (€1,600) per head contributing to the remaining 31%.

Biogenera has conceived and developed MyGeneraTM, a unique and highly innovative proprietary biotechnology platform that enables the identification of novel DNA drugs that act directly by blocking mutated genes that cause disease. Biogenera’s new drugs aim to block the causes of diseases, achieving maximum therapeutic efficacy and minimal or no toxicity, and constitute a great innovation compared to many current therapies that are ineffective and often toxic.

The company was founded by Roberto Tonelli, researcher of Pharmacology and Biotechnology at the University of Bologna with over 20 years of experience in the field and more than 150 scientific publications in international peer-reviewed journals, and Andrea Pession, Professor of Pediatrics at the University of Bologna and Director of the Pediatric Oncology Clinic at the Policlinico Sant’Orsola in Bologna.


(Featured image by CC BY 2.0 via Flickr)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Crowdfunding buzz, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

J. Frank Sigerson is a business and financial journalist primarily covering crypto, cannabis, crowdfunding, technology, and marketing. He also writes about the movers and shakers in the stock market, especially in biotech, healthcare, mining, and blockchain. In the past, he has shared his thoughts on IT and design, social media, pop culture, food and wine, TV, film, and music. His works have been published in,, Seeking Alpha, Mogul, Small Cap Network, CNN,, among others.